"Hepatocyte growth factor as an enhancer of NMDA currents and synaptic plasticity in the hippocampus." Neuroscience
Brickman, A
By week 16, a larger proportion of AXA1125-treated subjects (3540%) than those in the placebo group (825%) reached clinically relevant thresholds for MRI-PDFF reductions of 30%, ALT reductions of 17 IU/L, and cT1 reductions of 80 ms
10.Rodriguez-Rodriguez, J
Weiss JS, James WD, Cooper KD
Mice deficient in GPR43 exhibit an exacerbated colitis-like phenotype, while administration of SCFAs, including butyrate, ameliorates disease in wild-type but not GPR43-deficient animals, underscoring the receptors essential role in SCFA-mediated intestinal protection (Masui et al., 2013